FDA Recalls The W.S. Badger Company's Mineral Sunscreen Over Critical Labeling Deficiencies
The W.S. Badger Company, Inc. faced a Class III FDA recall for its BADGER 50 Mineral Sunscreen due to missing drug facts panels and usage directions. This event, now terminated, underscores critical compliance risks for OTC products. Decision-makers must reinforce labeling quality control to prevent market disruptions and ensure regulatory adherence, especially for zinc oxide formulations.
FDA Recall Details: The W.S. Badger Company's Labeling Non-Compliance for Mineral Sunscreen
The U.S. Food and Drug Administration (FDA) initiated a Class III recall, D-0209-2025, for The W.S. Badger Company, Inc.'s "BADGER 50, ADVENTURE SPORT MINERAL SUNSCREEN WITH CLEAR ZINC." This voluntary, firm-initiated action, commencing on January 17, 2025, addressed a critical labeling deficiency on 4,834 tins of the 2.4 oz product, which contains uncoated 25% zinc oxide. Specifically, the finished product was found to be potentially missing the essential drug facts panel, the product barcode, and directions for use. This particular lot, identified as LOT# 091923A with an expiration date of September 19, 2026, was distributed nationwide across the USA from the company's facility at 768 Route 10, Gilsum, NH 03448-7503. For procurement directors, this event highlights the imperative of stringent quality assurance protocols extending to final product packaging and labeling. A missing drug facts panel on an Over-The-Counter (OTC) drug like sunscreen represents a significant regulatory non-compliance, potentially exposing consumers to misuse and the recalling firm to legal liabilities. Supply chain VPs must ensure their supplier agreements include robust clauses for labeling accuracy and verification, particularly for products containing active pharmaceutical ingredients like zinc oxide, to safeguard against similar disruptions and maintain market integrity.
Operational Resolution and Supply Chain Vigilance Post-Recall Termination
The FDA officially terminated Recall D-0209-2025 on July 7, 2025, indicating that The W.S. Badger Company, Inc. has successfully addressed the labeling deficiencies for the affected BADGER 50 sunscreen lot. While a Class III recall signifies that exposure to the product is not likely to cause adverse health consequences, the underlying issue of missing critical labeling components—such as the drug facts panel and directions for use—still represents a lapse in quality control. The recall was firm-initiated, suggesting the company identified and acted upon the problem voluntarily, a factor that can positively influence regulatory perception. For regulatory affairs heads, the termination status provides closure on this specific event but serves as a crucial reminder of the continuous need for vigilance in manufacturing and labeling processes. It underscores that even seemingly minor deviations can trigger nationwide recalls, impacting operational efficiency and brand reputation. Supply chain VPs should leverage such incidents to review their internal audit schedules and supplier performance metrics, focusing on the robustness of final product release procedures. Ensuring that all distributed products, especially those classified as OTC drugs, meet all labeling requirements is fundamental to avoiding future regulatory actions and maintaining uninterrupted market supply.
Broader Industry Implications for OTC Product Labeling and Active Ingredients
This incident involving The W.S. Badger Company, Inc. extends beyond a single product recall, offering broader lessons for the global chemical and life sciences industry, particularly for manufacturers and distributors of Over-The-Counter (OTC) drug products. The core issue—missing essential labeling information on a sunscreen containing 25% zinc oxide—highlights the stringent regulatory environment governing products with active pharmaceutical ingredients (APIs). The FDA mandates comprehensive labeling, including drug facts panels, barcodes, and clear directions, to ensure consumer safety and informed use. For business development executives, this event underscores the critical importance of due diligence when forming partnerships or acquiring product lines in the OTC space. A supplier's history of regulatory compliance, particularly concerning labeling integrity, is a key indicator of operational maturity and risk. Procurement directors sourcing finished OTC products or bulk active ingredients like zinc oxide must integrate labeling compliance checks into their supplier qualification and ongoing monitoring programs. Regulatory affairs teams should proactively review their labeling control systems, implementing redundant checks and employee training to prevent similar oversights that could lead to costly market withdrawals, reputational damage, and potential enforcement actions across their distribution networks in the United States.